Compassionate use programmes enable people with life-threatening, long-lasting or seriously disabling illnesses to use drugs that have not yet been authorised. This is usually only for drugs that are near to drug approval, especially for people who would be excluded from research studies.
This is similar to, and sometimes called, a named-patient programme.
Information on compassionate access in the EU.
DAA (direct acting antiviral) – new hepatitis C drugs that work directly against the hepatitis C virus (HCV).
The following links are to UK prescribing information for DAA combinations plus ribavirin.
Elbasvir/grazoprevir
https://bnf.nice.org.uk/drugs/elbasvir-with-grazoprevir/
Sofosbuvir/ledipasvir
https://bnf.nice.org.uk/drugs/ledipasvir-with-sofosbuvir/
Glecaprevir/pibrentasvir
https://bnf.nice.org.uk/drugs/glecaprevir-with-pibrentasvir/
Sofosbuvir/velpatasvir
https://bnf.nice.org.uk/drugs/sofosbuvir-with-velpatasvir/
Sofosbuvir/velpatasvir/voxilaprevir
https://bnf.nice.org.uk/drugs/sofosbuvir-with-velpatasvir-and-voxilaprevir/
Ribavirin (RBV)
https://bnf.nice.org.uk/drugs/ribavirin/
Additional information is available from the MHRA website.
https://products.mhra.gov.uk/
Tmax – the time taken for a drug to reach the highest (maximum) concentration.
foetoplacental circulation is the blood supply in the foetus and placenta.
fixed dose combination (FDC) – several drugs combined in one tablet at a standard dose.